KR20230158033A - 주요 우울 장애의 치료를 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 - Google Patents

주요 우울 장애의 치료를 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 Download PDF

Info

Publication number
KR20230158033A
KR20230158033A KR1020237034937A KR20237034937A KR20230158033A KR 20230158033 A KR20230158033 A KR 20230158033A KR 1020237034937 A KR1020237034937 A KR 1020237034937A KR 20237034937 A KR20237034937 A KR 20237034937A KR 20230158033 A KR20230158033 A KR 20230158033A
Authority
KR
South Korea
Prior art keywords
treatment
compound
subject
degrees
course
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237034937A
Other languages
English (en)
Korean (ko)
Inventor
로베르트 알폰소 라세르
제임스 도허티
제프리 마틴 조나스
스티븐 제이 케인스
한단 군두즈-브루스
조이 리사 던바
밤방 세노아지 아디위자야
Original Assignee
세이지 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세이지 테라퓨틱스, 인크. filed Critical 세이지 테라퓨틱스, 인크.
Publication of KR20230158033A publication Critical patent/KR20230158033A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020237034937A 2021-03-17 2022-03-17 주요 우울 장애의 치료를 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 Pending KR20230158033A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163162501P 2021-03-17 2021-03-17
US63/162,501 2021-03-17
US202163284592P 2021-11-30 2021-11-30
US63/284,592 2021-11-30
PCT/US2022/020716 WO2022197901A1 (en) 2021-03-17 2022-03-17 A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder

Publications (1)

Publication Number Publication Date
KR20230158033A true KR20230158033A (ko) 2023-11-17

Family

ID=81327141

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237034937A Pending KR20230158033A (ko) 2021-03-17 2022-03-17 주요 우울 장애의 치료를 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드

Country Status (11)

Country Link
US (1) US20240245711A1 (https=)
EP (1) EP4308162A1 (https=)
JP (1) JP2024510436A (https=)
KR (1) KR20230158033A (https=)
AU (1) AU2022238365A1 (https=)
BR (1) BR112023018607A2 (https=)
CA (1) CA3213744A1 (https=)
IL (1) IL305858A (https=)
MX (1) MX2023010728A (https=)
TW (1) TW202300156A (https=)
WO (1) WO2022197901A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102396328B1 (ko) * 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
EP3612186A1 (en) * 2017-04-18 2020-02-26 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations
WO2019051264A1 (en) * 2017-09-07 2019-03-14 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS AND METHODS OF USE
CA3103421A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
KR20230041049A (ko) 2020-07-20 2023-03-23 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법
US20230372364A1 (en) * 2020-10-01 2023-11-23 Jeremy Hill Method of treating gaba mediated disorders

Also Published As

Publication number Publication date
EP4308162A1 (en) 2024-01-24
BR112023018607A2 (pt) 2023-10-24
JP2024510436A (ja) 2024-03-07
MX2023010728A (es) 2024-02-12
WO2022197901A1 (en) 2022-09-22
TW202300156A (zh) 2023-01-01
AU2022238365A1 (en) 2023-09-21
US20240245711A1 (en) 2024-07-25
IL305858A (en) 2023-11-01
CA3213744A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
KR20230158033A (ko) 주요 우울 장애의 치료를 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
US20250339447A1 (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20250295674A1 (en) Neuroactive steroids for treatment of cns-related disorders
US20240216395A1 (en) 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
AU2022267304A1 (en) Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female
KR20220112803A (ko) 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
JP2022507103A (ja) コルチコステロイドを投与する方法
CN117098554A (zh) 用于治疗重度抑郁障碍的19-去甲c3,3-二取代c21-n-吡唑基类固醇
JP2024544777A (ja) ハンチントン病の治療のための神経活性ステロイド
WO2023159035A1 (en) Neuroactive steroids for treatment of cns-related disorders
CN118765200A (zh) 用于治疗亨廷顿氏病的神经活性类固醇
EA044015B1 (ru) Дейтетрабеназин для лечения дискинезии при церебральном параличе

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231012

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250314

Comment text: Request for Examination of Application